As previously reported, BofA analyst Andrew Obin upgraded 3M to Buy from Neutral with a price target of $120, up from $105. The firm sees the new CEO refocusing the company on growth and operations and argues that the change in management “comes at an opportune time” after 3M spent the past several years focusing on litigation and exiting PFAS manufacturing as well as spinning out its Healthcare business. With the major litigation settlements behind it and uncertainty reduced around remaining lawsuits, investors are likely to focus on improving operations and potential cyclical leverage, the analyst contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMM:
- 3M price target raised to $118 from $112 at Barclays
- 3M call volume above normal and directionally bullish
- Intel upgraded, Texas Instruments initiated: Wall Street’s top analyst calls
- Vertical Research upgrades 3M to Buy, says risk/reward ’tilts clearly to upside’
- 3M upgraded to Buy from Hold at Vertical Research
Questions or Comments about the article? Write to editor@tipranks.com